Medicines360 Names Pamela Weir as COO

Medicines360 Names Pamela Weir as COO

SAN FRANCISCO--(BUSINESS WIRE)--Medicines360, a non-profit pharmaceutical company, today announced Pamela Weir has been appointed as Chief Operating Officer. Ms. Weir brings extensive pharmaceutical experience and a proven track record of building and leading successful brands, therapeutic portfolios and high performance teams.

"As we move closer to approval and launch of our IUD, it has become increasingly important to engage leaders who will ensure that we achieve product success and sustainability, while simultaneously directing our primary goal of affordable access to safe and effective contraception"
Ms. Weir's 25-year pharmaceutical career spans commercial functions in international and domestic marketing, communications, sales and access in addition to strategic planning, business development and operations. She has broad partnership experience with pharmaceutical and biotech companies as well as patient and physician groups. Ms. Weir has successfully launched and built products in the U.S. and all major markets internationally, while based in the U.S., Canada and Europe. In addition, she had led the development of companies' corporate strategy from discovery research through development, launch and post-launch.

Prior to joining Medicines360, Ms. Weir served as Vice President of Marketing for Alpharma(King) Pharmaceuticals and Nycomed Pharmaceuticals, leading domestic and global teams. She also held commercial leadership positions in Bayer Pharmaceuticals and Sanofi-Aventis.

"As we move closer to approval and launch of our IUD, it has become increasingly important to engage leaders who will ensure that we achieve product success and sustainability, while simultaneously directing our primary goal of affordable access to safe and effective contraception," said Victoria Hale, PhD, Medicines360 Founder & CEO. "Pamela's commercial expertise, partnership experience, patient-focused approach and passion will drive Medicines360 towards its self-sustaining business model - launching our first women's health product and establishing access for women across all channels. Her strategic leadership will be a great asset in driving Medicines360 toward our social mission of empowering all women."

Ms. Weir holds a Bachelor of Science and an MBA. She and her family are relocating to the San Francisco area from North Carolina.

About Medicines360

Medicines360 is a non-profit pharmaceutical company and social enterprise. Funded by an anonymous donor, we are working toward self-sustainability through commercial sales revenue by developing innovative, affordable, and sustainable medical solutions for women. Profit is a means of achieving our mission, not our motive; we exist to meet the medical needs of all women. For press release and more information, visit: www.medicines360.org.

Contacts

Medicines360
Media:
Sedef Onder, 212-884-9959
[email protected]

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.